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The addition of protease inhibitors, boceprevir or telaprevir, to
peginterferon + ribavirin (PegIFN/RBV) increases the frequency
as well as the severity, and hence, clinical relevance of anemia,
which has now become one of the major complications associ-
ated with triple therapy. Most signiﬁcant factors associated with
anemia in patients receiving triple therapy include older age,
lower body mass index (BMI), advanced ﬁbrosis, and lower base-
line hemoglobin. The variability in inosine triphosphate pyro-
phosphatase (ITPA) gene, which encodes a protein that
hydrolyses inosine triphosphate (ITP), has been identiﬁed as an
essential genetic factor for anemia both in dual and triple ther-
apy. The correct management of anemia is based on anticipation,
characterization and therapeutic management. Basically, anemia
can be characterized in 3 types: ferropenic (mostly in fertile
women), thalassemic type hemolytic anemia, and anemia from
chronic processes. Functional deﬁcit of iron should also be
excluded in patients with normal ferritin and lower saturation
of transferrin. Ribavirin dose reduction and epoetin, sequentially,
are indicated in the management of anemia. Epoetin non-
response can be caused by lack of time, type of anemia, functional
iron deﬁcit or erythropoietin resistance. In the transplantation
setting, adding a protease inhibitor to PegIFN/RBV results in a sig-
niﬁcant increase in the incidence and severity of anemia and, as a
consequence, a greater need for epoetin, transfusions, and ribavi-
rin dose reductions. Packed red cell transfusions are utilized
when hemoglobin decreases to less than 7.5 g/dl and/or there
are clinical symptoms and/or there is no response to other
therapeutic measures.Journal of Hepatology 20
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Anemia is a major complication of antiviral therapy in chronic
hepatitis C. With dual therapy, and despite its negative impact
on quality of life, it was a desirable effect due to its association
with higher sustained viral response rates. In patients treated
with triple therapy, the impact of anemia on outcome is contro-
versial; its incidence though is signiﬁcantly higher and the man-
agement in this scenario is more complex, frequently requiring
ribavirin dose reduction, epoetin and, in some cases, blood trans-
fusions, jeopardizing the ﬁnal efﬁcacy of triple therapy.
In this review, we will try to answer the questions that physi-
cians face regarding the management of anemia among patients
treated with telaprevir or boceprevir triple therapy. We highlight
the most relevant aspects with regards to the incidence of ane-
mia, its clinical course, factors implicated in its development,
characterization, and management.What are the deﬁnition, etiology (pathophysiological
mechanism), incidence and natural course of anemia in
patients receiving triple therapy?
Treatment of chronic hepatitis C depends on viral genotype.
While patients with hepatitis C virus (HCV) genotype 1 are trea-
ted with triple therapy based on protease inhibitors (telaprevir or
boceprevir) + peginterferon + ribavirin (PegIFN), those with HCV
genotypes 2–6 are treated with dual therapy of PegIFN/RBV
[1,2]. Anemia (deﬁned in HCV studies as hemoglobin levels
<10 g/dl) is one of the major adverse events in patients treated
with PegIFN/RBV due to the hemolytic effect of ribavirin and,
on rare occasions, the bone marrow depression induced by inter-
feron. The addition of protease inhibitors, boceprevir, and
telaprevir, increases the frequency as well as the severity, and
hence, clinical relevance of anemia, which has now become one13 vol. 59 j 1323–1330
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of the major complications associated with triple therapy [1]. In
the pivotal studies of telaprevir and boceprevir, more than one in
three patients developed anemia (hemoglobin <10 g/dl) with rates
that varied between 29% and 49%, respectively [3–7]. More specif-
ically, 34% and 8% of those treated with telaprevir-based therapy
had a decrease in hemoglobin to levels <10 g/dl and 8 g/dl, respec-
tively (compared to 14% and 2%, respectively, with dual therapy
[5–7]). In the trials with boceprevir, the levels of hemoglobin were
reduced to levels between 10 and 8.5 g/dl in 41–45% of patients
(compared to 26% with dual therapy) and 5–9% reached levels of
hemoglobin <8.5 g/dl (compared to 4% with dual therapy) [3,4].
In cirrhotic patients, the anemia is greater in severity and fre-
quency than in non-cirrhotic patients [8]. In Phase II/III treat-
ment-naïve patients receiving telaprevir, around 67% of cirrhotic
patients developed signiﬁcant anemia compared to 46% of non-cir-
rhotic individuals [6]. In treatment-experienced patients, these
percentages were 42% vs. 27%, respectively [7]. In Phase III studies
of treatment-naïve and non-responder patients receiving bocepre-
vir, 54% of the cirrhotic patients vs. 46% of the F0-F2 patients devel-
oped anemia (deﬁned as hemoglobin <11 g/dl) [4,5]. In clinical
practice, studies including patients with cirrhosis or advanced
ﬁbrosis showed this percentage increased signiﬁcantly. Neverthe-
less, less than 3% of patients discontinued therapy because of ane-
mia attributable to protease inhibitors and/or ribavirin [8–10].
Observed rates of anemia in clinical practice and management
outcomes are shown in Table 1.
In patients receiving dual therapy, the levels of hemoglobin
decrease by about 3 g/dl during the ﬁrst 3 months of therapy.
The addition of a protease inhibitor (telaprevir or boceprevir)
represents an additional decrease of around 1 g/dl as well as a
modiﬁcation in the rapidity with which these changes occur.
The changes in hemoglobin concentration with telaprevir are
practically identical to those of boceprevir during the ﬁrst
3 months of triple therapy. A sharp decrease in the levels of
hemoglobin occurs in the ﬁrst 4 months, with the most signiﬁ-
cant decrease occurring between weeks 2 and 6. The lowest value
of hemoglobin is observed between weeks 12 and 14. After this,
the changes in hemoglobin concentration diverge between
patients treated with telaprevir and those treated with bocepre-
vir. At the end of treatment with telaprevir, at week 12, the val-
ues of hemoglobin increase gradually and reach the values of the
control arm of dual therapy. Conversely, with boceprevir, the lev-
els follow a pattern in which the decrease in hemoglobin concen-
tration is maintained up to the end of treatment at week 48.
Based on the natural history of anemia, most experts recommend
baseline complete blood count before starting therapy followed
by monitoring levels at weeks 2, 4, 8, and 12 during the ﬁrst
12 weeks of therapy. In patients at high risk of anemia (see later)
or those with comorbidities that increase the risks associated
with anemia, stricter monitoring is required, i.e., weekly testing
(Figs. 1 and 2).What baseline and on-treatment factors predict more severe
anemia with triple therapy? Is there a factor predictive of a
sharp decrease in hemoglobin concentration during
treatment?
Factors associated with anemia both with dual and triple therapy
are shown in Table 2. During dual therapy, factors predictive of
anemia include age above 50 years, female gender, low platelet1324 Journal of Hepatology 2013count (<150,000 platelets/mm3), baseline renal dysfunction (cre-
atinine >1.5 g/dl), fast decrease of hemoglobin (>1.5–2 g/dl in
15 days), high ribavirin dose (>12 mg/kg), haptoglobin phenotype
(Hp 1-1) and the presence of high function inosine triphospha-
tase (ITPA) genotype [9,10]. Baseline factors associated with ane-
mia among naïve patients treated with telaprevir-based triple
therapy include low baseline hemoglobin, high ribavirin doses,
older age, and presence of cirrhosis. In turn, baseline factors asso-
ciated with anemia in experienced patients receiving telaprevir-
based triple therapy include older age (>50 years), lower body
mass index (BMI <25 kg/m2), and lower baseline hemoglobin
[11]. In addition, when pretreatment factors were taken into
account, low haemoglobin levels (<13 g/dl) at week 2 was a sig-
niﬁcant prognostic indicator for the development of treatment-
emergent anemia. Both in naïve and experienced patients,
women developed more frequently anemia than men, but this
was thought to be related to lower baseline haemoglobin values,
lower BMI, and higher ribavirin dosing in females [11]. In turn, in
patients receiving boceprevir, the development of anemia is
inﬂuenced by baseline levels of hemoglobin, female gender, older
age (>40 years), use of statins, a decrease in hemoglobin during
prior therapy (or during the lead-in phase) with PegIFN/RBV,
and/or the rate of creatinine clearance [12,13]. The mechanisms
that explain these associations are not completely understood.
Low body mass index patients can be overexposed to protease
inhibitors and/or ribavirin. In turn, patients with low baseline
hemoglobin levels and older patients are inherently expected to
be at greater risk of developing anemia; patients with advanced
ﬁbrosis, particularly cirrhotic patients, may have a special sensi-
tivity to the hemolytic effects of ribavirin, or perhaps also to the
central anemia induced by protease inhibitors. Finally, in patients
treated with a lead-in phase with PegIFN/RBV, the decrease in the
levels of hemoglobin can help predict further development of
anemia, so that in those with a decrease of more than 3 g by week
4, the risk of developing anemia in the following 4 weeks of triple
therapy is greater than 80%. Finally, genetic factors inﬂuence ane-
mia in both dual and triple therapy [15]. The variability in inosine
triphosphate pyrophosphatase (ITPA) gene, which encodes a pro-
tein that hydrolyses inosine triphosphate (ITP), has been identi-
ﬁed as an essential factor in a genome-wide association study
(GWAS) [10] in patients receiving PegIFN/RBV. Single nucleotide
polymorphisms (SNP) rs1127354 and rs7270101 affect the
expression of ITPA. Individuals with ITPA deﬁciency gain protec-
tion from the hemolytic anemia induced by ribavirin, as the accu-
mulation of ITP in erythrocytes increases the toxicity of purine
analogue drugs. Thompson et al. conﬁrmed this ﬁnding in 304
patients with HCV-1, as well as the decrease of ribavirin dose
reduction in patients with polymorphisms that cause ITPase deﬁ-
ciency [16]. Subsequent studies have shown similar conclusions
in patients on dual therapy [17]. There are a few studies about
the role of ITPA on triple therapy. Suzuki et al. [18] assessed 61
HCV-1 patients treated with triple therapy with PegIFN, ribavirin,
and telaprevir. Ribavirin dose reduction and nadir haemoglobin
were compared between patients with favourable (CA/AA) and
unfavourable (CC) genotypes in the ITPA gene (rs1127354).
Decreases in haemoglobin levels were greater in patients with
CC than CA/AA genotypes at week 2 and week 4, as well as at
the end of treatment. The total ribavirin dose during the overall
period of 24 weeks of therapy was comparable between patients
with CC and CA/AA genotypes. However, ribavirin dose had to be
reduced more often in patients with CC than CA/AA genotypesvol. 59 j 1323–1330
Table 1. Observed anemia rate in clinical practice and its management.
CUPIC cohort [8] EAP telaprevir cohort [33] Veterans cohort [34]
TPV
n = 205
BOC
n = 292
TPV
n = 609
TPV
n = 198
BOC
n = 661
Anemia (grade 2), Hb 8-9.9 g/dl 19% 23% - 37% 43%
Anemia (grade 3-4), Hb <8 g/dl 12% 4% 29% 13% 7%
RBV dose reduction 13% 11% 34% 38% 44%
ESA use 54% 46% 24% 26% 25%
Blood transfusion 16% 6% 11% 8% 5%
TPV, telaprevir; BOC, boceprevir; RBV, ribavirin; ESA, erythropoeietic stimulating agents.
JOURNAL OF HEPATOLOGYwhile receiving telaprevir. The authors concluded that ITPA poly-
morphism inﬂuences haemoglobin levels during triple therapy,
especially while telaprevir is given. Similar results were obtained
by Chayama et al. [19]. They included 94 Japanese patients with
HCV genotype 1 treated with PegIFN, ribavirin and telaprevir.
Patients with unfavourable (CC) ITPA SNP rs1127354 genotype
required RBV dose reduction earlier than did patients with other
genotypes. Besides, sustained virological response was not asso-
ciated with ITPA polymorphism. In summary, ITPA genotyping is
able to detect HCV-infected patients, treated with dual or triple
therapy, who have higher risk of developing anaemia. These
patients should be monitored more closely with, perhaps, earlier
reduction of ribavirin dose.Does the development of anemia impact sustained viral
response?
Interestingly,withdual therapy, thedevelopmentof anemia,despite
its associationwith poorer quality of life and potential development
of severe complications, was considered a desirable effect since it
was an indirect marker of higher efﬁcacy, i.e., developing anemia
was an indirect conﬁrmation that the patient had adhered to the
treatment, and that the ribavirin molecule had entered not only
the hepatocyte but also the erythrocyte and, in doing so, had led to
the adverse as well as desired effects at the same time.
In patients receiving telaprevir in Phase III trials (ADVANCE
and ILLUMINATE), in which the percentage of cirrhotic patients
was low, the efﬁcacy was similar regardless of the development
of anemia (74% in those with anemia vs. 73% in those without)
or the need for ribavirin dose reduction (76% in those requiring
ribavirin dose reductions vs. 72% in those without dose reduc-
tions) [20]. The results with boceprevir are different. In a post-
hoc analysis of Phase III trials (SRINT-2 & RESPOND-2), SVR rates
were greater in patients who developed anemia compared to
those who did not develop this complication [13]. A sustained
viral response was achieved in 58% (212/363) of treatment-naïve
patients who did not develop anemia, 74% (95/129) of those who
developed anemia and were treated with erythropoietin, 78%
(29/37) of those who developed anemia and needed a dose reduc-
tion of ribavirin, 71% (109/153) of those who needed erythropoi-
etin and ribavirin dose reductions and in 68% (30/44) of those
who developed anemia and did not need speciﬁc treatment. In
treatment-experienced patients with treatment failure (relapsers
or partial responders), a sustained viral response was achieved in
50% of those who did not develop anemia compared to 76% of
those who did.Journal of Hepatology 2013What is the appropriate dose of ribavirin in triple therapy?
Is ribavirin necessary with the use of the new protease
inhibitors?
The optimum dose of ribavirin depends on body weight. In the
PegIFN alfa-2b registration study, 10.6 mg/kg/d was established
as the minimum effective dose. Subsequently, the results of treat-
ment with PegIFN/RBV established the initial treatment dose of
15 mg/kg/d [1,3]. In clinical practice, when PegIFN alfa 2a is
administered in patients of <75 kg body weight, a dose of
1000 mg/d is used while 1200 mg/d is recommended for body
weightP75 kg. If PegIFN alfa 2b is used, the recommended dose
is 800 mg/d for patients 665 kg, 1000 mg/d for patients between
65 and 85 kg, 1200 mg/d for those between 85 and 105 kg, and
1400 mg/d for P105 kg bodyweight. Currently, there is no evi-
dence to justify the use of a lower initial dose. Besides, low-dose
ribavirin was associated with a high rate of viral breakthrough
and rate of relapse in a phase II study of naïve patients [14]. In
this phase II study, a cohort of patients received BOC-based triple
therapy with a low dose of ribavirin (ranging from 400 to
1000 mg/d). The sustained viral response rate was only 35% com-
pared to 75% in the cohort receiving triple therapy and a high
dose of ribavirin (800–1400 mg/d). In the near future, data from
clinical trials that are being conducted in speciﬁc populations
(co-infected or transplanted) may indicate that a lower, ﬁxed
dose of 800 mg can be adequate with triple therapy. Although
ribavirin dose reductions (and perhaps lower starting doses) do
not impair sustained viral response rates (see question 5), ribavi-
rin is necessary when using protease inhibitors to achieve sus-
tained viral response rates greater than those achieved with
dual therapy. If ribavirin is discontinued, it should be restarted
within 3 days of its discontinuation. If not possible, protease
inhibitors should be also discontinued.What is the most effective strategy to manage anemia during
triple therapy: to decrease ribavirin dose or to administer
epoetin? Do the reductions of ribavirin dose compromise
sustained viral response rates? Are transfusions a good
solution in the presence of anemia, and when should they be
administered?
The correct management of anemia is based on anticipation,
characterization, and therapeutic management. In order to
anticipate the development of anemia, the dose of ribavirin
should be adjusted to the patient’s weight; baseline hemoglo-
bin levels should be measured and if found to be low, strictvol. 59 j 1323–1330 1325
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Fig. 1. Representation of the mechanism of anemia in patients receiving
PegIFN/RBV or protease inhibitor-based triple therapy. A balance between
production and lysis is crucial. At the top, equilibrium between lysis and
production in healthy people. In the middle, role of ITPA on ribavirin-induced
hemolytic anemia, showing an overwhelming lysis. At the bottom, central anemia
induced by protease inhibitors in which red cell production is compromised.
Reviewmonitoring should be implemented. Both the European Associa-
tion for the Study of the Liver (EASL) and the American Associa-
tion for the Study of Liver Disease (AASLD) recommend levels
of haemoglobin >12 g in females and >13 g in males to start treat-
ment [1,2]. Initiating therapy below these values is not contrain-
dicated but each case needs to be assessed individually due to the
potential for severe adverse events. Furthermore, in a patient
with a history of clinically signiﬁcant anemia in previous dual
therapy, the patient should be informed that the anemia pro-
duced by dual therapy can be exacerbated by the addition of a
protease inhibitor. These cases require a closer monitoring,
mostly in the presence of comorbidities. Since both protease
inhibitors are capable of producing clinically signiﬁcant anemia,
a history of anemia during a previous treatment should not inﬂu-
ence the election of a speciﬁc protease inhibitor. In addition, the1326 Journal of Hepatology 2013doses of protease inhibitor should not be modiﬁed. If considered
appropriate, in some cases, the dose of ribavirin can be reduced
and/or epoetin administered preemptively [13].
The characterization of anemia is the second useful tool in
the management of this complication. In general, there are 3
types of anemia: ferropenic anemia (mostly in fertile women),
thalassemic type hemolytic anemia, and anemia from chronic
processes. In the latter, a functional deﬁcit of iron, a clinical situ-
ation that occurs in patients with ferritin levels higher than
100 mg/ml despite the presence of ferropenia, might be involved.
In these cases, ferritin acts as an acute phase reactant generating
false negative results. Transferrin saturation index, levels of
transferrin soluble receptor (sRfT) and the reticulocytic hemoglo-
bin concentration should be measured to make a deﬁnitive diag-
nosis. A functional iron deﬁcit is characterized by a transferrin
saturation index <20%, a concentration of sRfT >5 mg/dl or an
sRfT/log quotient of ferritin <1.5. In patients treated with PegIFN,
ribavirin and protease inhibitors, 3 types of anemia have been
described: (i) hemolytic anemia characterized by degradation of
haptoglobin; (ii) central anemia characterized by the absence of
a reticulocyte response; and (iii) mixed anemia in which hemoly-
sis and central anemia occur simultaneously. Both, reduction of
ribavirin dose and administration of epoetin are used in the
management of anemia. In the telaprevir trials registered to
date, the use of epoetin was not allowed and the management
of anemia was solely based on decreasing the ribavirin dose. Con-
versely, in the registered trials of boceprevir, dose reductions of
ribavirin as well as epoetin administration were allowed at the
discretion of the investigator. Retrospective analyses of these reg-
istered trials have shown that with both protease inhibitors, the
decrease of ribavirin dose does not compromise sustained viral
response rates. Interestingly, in patients treated with dual ther-
apy, a decrease in the ribavirin dose was shown to compromise
the success of therapy, mostly if the reduction was performed
in the ﬁrst weeks of therapy when the patient was still viremic
[21]. However, the results of this study were not conﬁrmed in
the post-hoc analysis of the IDEAL study [22]. Moreover, sub-anal-
yses of the studies using triple therapy advocate that the dose of
ribavirin can be safely reduced without compromising the efﬁ-
cacy, irrespectively of the timing of dose reduction or the detect-
ability of HCV RNA in serum [23]. Indeed, in subanalysis of the
registered trials of triple therapy with telaprevir in treatment-
naïve patients (ADVANCE and ILLUMINATE), no signiﬁcant differ-
ences in sustained viral response rates were observed between
patients in whom the dose of ribavirin was reduced vs. those in
whom it was not (79% vs. 75%, respectively) [13]. The same
results were obtained when analyzing previously-treated
patients (REALIZE). In this setting, the outcomes were indepen-
dent of the type of previous response: relapsers (82% vs. 83%),
partial responders (66% vs. 50%) or non-responders (31% vs.
45%) [13]. Similar results were obtained in the subanalysis of reg-
istered trials of triple therapy with boceprevir in treatment-naïve
patients (SPRINT-2) and previously-treated patients (RESPOND-
2) in which there were no differences in the rates of sustained
viral response between patient in whom the dose of ribavirin
was reduced vs. those in whom it was not [24]. In a recent ran-
domized study, ribavirin dose reduction was compared to epoetin
use in the management of anemia induced by triple therapy with
boceprevir in treatment-naïve patients [12]. Patients were ran-
domized when they became anemic (hemoglobin <10 g/dl, or if
the rate of hemoglobin decline suggested that the value wouldvol. 59 j 1323–1330
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Fig. 2. Management of anemia in patients with chronic hepatitis C genotype 1 receiving protease inhibitor-based triple therapy with telaprevir or boceprevir.
JOURNAL OF HEPATOLOGYbe <10 g/dl before the next protocol speciﬁed visit and the value
was <11 g/dl) to receive epoetin (40,000 IU s.c./week) or dose
reductionof ribavirin (200 mg in 200 mg). Therewere 687patients
included. Anemia (hemoglobin <10 g/dl) developed in 500patients
(72%) who were then randomized to receive epoetin (n = 251) or
ribavirin dose reduction (n = 249). The rates of sustained viral
response were almost identical; 178/249 (71%) in the dose reduc-
tion arm and 178/251 (71%) in the epoetin arm. Indeed, sustained
viral response rates were similar between both arms regardless
of timingof theﬁrst ribavirin reductionandHCV-RNAdetectability
at the time of randomization. Furthermore, in the registered trials
as well as in this prospective study, no signiﬁcant differenceswere
observed in sustained viral response rates as a function of ribavirin
dose reduction up to 50%. The viral response was impaired if the
ribavirin dosewas lower than 50% (sustained viral response of only
18%). There is a paucity of data on the inﬂuence of ribavirin reduc-
tion in cirrhotic patients due to the low number of cirrhotic
patientshavingbeenenrolledeither inpivotal trialswith telaprevir
and boceprevir, or in randomized trials aimed at assessing the best
strategy for anemia management. In the above trial, no major dif-
ferences in sustained viral response were observed in cirrhotic
patients (n = 60) who had ribavirin dose reduction vs. those who
were treatedwith epoetin (57% vs. 64%). It is important to note that
38% of patients randomized in the EPO arm needed a secondary
intervention to control the anemia while this second intervention
was only needed in 18% of the patients in the ribavirin arm. This
treatment failure rate occurred in 56% of cirrhotics. In this trial,
the ribavirin dose reduction was performed by increments of
200 mg and of 400 mg if the initial dose of RBV was 1400 mg/
day. In summary, ribavirin dose reduction, its magnitude and the
timing when it occurs have no inﬂuence on viral clearance rates.
Based on these results, ribavirin dose reduction has become the
ﬁrst measure in the management of anemia. Whether the reduc-
tion should be performed progressively (200 mg in 200 mg) or
more abruptly (directly to 600 mg) requires further investigation.
In addition, given that the data from clinical trials are very limited
regarding subgroup analyses, there still remains a need to conﬁrm
whether the trials’ ﬁndings remain true in standard clinical prac-
tice, particularly when treating cirrhotic patients.Journal of Hepatology 2013In case of no response to ribavirin dose reduction, epoetin can
be administered. However, ribavirin has an unusual pharmacoki-
netic proﬁle that does not follow the standard models of absorp-
tion, distribution, and elimination. It is characterized by a very
slow, and variable, eliminatory phase following rapid absorption
and distribution phases. The half-life of elimination increases
progressively from 79 h with a single dose up to 274–298 h
(about 12 days) with multiple doses [24]. Based on these data,
waiting 7–10 days to check whether ribavirin dose reductions
have resulted in an effective response seems an appropriate
time-frame. In addition, and based on available data, it seems
appropriate to maintain, in case of anemia, a ribavirin dose
>60% of the baseline recommended dose and, if possible, to com-
plete at least 80% of the scheduled treatment duration [12,15,21].
Once the protease inhibitor is discontinued, evidence suggests
that while there is no contraindication to increasing the dose of
ribavirin, this strategy is not strictly required, i.e., the develop-
ment of anemia probably reﬂects a high exposure and sensitivity
to ribavirin. In cases in which the reductions of doses are drastic
(with doses of 600 mg/d), the aim should be to achieve a total
dose P60% of the dose prescribed [2].
Erythropoietin (EPO) is an essential factor in the production
of red cells. Essentially, EPO is produced in adults in the kidneys
(90–95%), especially in the interstitial ﬁbroblastic cells in the
internal cortex, and in smaller amounts in the liver, spleen, lungs,
testicles, and brain. Treatment with EPO (or ‘‘epoetin’’, as the
pharmaceutical preparation is termed) is, in general, well toler-
ated and severe adverse events are rare. Pain at the injection site,
headache and arterial hypertension are the most frequently
reported. Isolated cases of convulsion, thrombotic phenomena,
and red cell aplasia have also been described.
Epoetin is indicated in cases of ferropenic anemia, loss of red
cells (bleeding), increases in red cells destruction (associated
with anti-neoplastic, anti-viral or anti-inﬂammatory therapies)
and anemia due to reduced/lack of endogenous erythropoietin
typical of end-stage renal diseases. Different types of EPOs are
available: alfa epoetin, beta epoetin, omega epoetin, theta epoe-
tin, alfa darbepoetin, methoxy-polyethylene glycol beta epoetin,
and activating agents of the endogenous erythropoietin receptor.vol. 59 j 1323–1330 1327
Table 2. Predictive factors associated with anemia in patients treated with dual or triple therapy.
Type of treatment/Factor Dual therapy Triple therapy with telaprevir Triple therapy with boceprevir
Age >50 yr >50 yr >40 yr
Sex Female Female in univariate analysis Female
Body mass index <23 kg/m2
Statin use Statin use
Baseline hemoglobin levels Lower baseline hemoglobin levels Lower baseline hemoglobin 
levels
Lower baseline hemoglobin 
levels
Stage of disease Cirrhosis
Renal function Creatinine >1.5 mg/dl; creatinine 
clearance <80 ml/min
Creatinine clearance <80 ml/min
Ribavirin dose >12 mg/kg
ITPA polymorphism ITPA polymorphism ITPA polymorphism ITPA polymorphism
On-treatment factors
weeks of treatment (>1.5-2 g/dl at 
week 2)
Low hemoglobin levels (<13 g/dl) 
at week 2
Degree of hemoglobin decrease 
during the lead-in phase
Fast hemoglobin drop during the first
Advanced fibrosis Advanced fibrosis
ReviewThose that have been most frequently used in the management of
anemia associated with triple therapy are alfa epoetin (40,000 IU/
week) and alfa darbepoetin (1.5 lg/kg/week) although, to date,
there are no convincing scientiﬁc arguments in favour of either
one. Although there is no ﬁxed protocol as to how and when to
initiate the administration of erythropoietin, most experts rec-
ommend its initiation if after three steps of 200 mg/d dose reduc-
tions over a period of 3 weeks, there is a failure to achieve
recovery or stabilization of hemoglobin levels. The nadir at which
to initiate erythropoietin is not ﬁxed; generally experts recom-
mend initiating EPO when the levels of hemoglobin remain lower
than 10 g/dl despite ribavirin dose reductions. In patients with
sharp decreases in hemoglobin (2 g/dl in 2 weeks, 3 g/dl in
4 weeks or 4 g/dl relative to baseline), but with levels between
10 and 12 g/dl, there needs to be a clinical assessment of the
risk-beneﬁt for the patient [25,26]. If there is resolution of symp-
toms and/or if the values of hemoglobin reach 10 to 12 g/dl,
either the dose should be reduced or, alternatively, the interval
extended until an optimal schedule is reached, which should then
be maintained during the remaining duration of antiviral treat-
ment. The doses of epoetin alfa and beta need to be decreased
by 25% of the baseline dose in case of increases of >1 g/dl hemo-
globin after 2 weeks of treatment, while a decrease of 49% is rec-
ommended when the drug used is darbepoetin. Discontinuation
of erythropoietin should be considered in patients who do not
respond after 8 weeks of therapy or if hemoglobin is >12 g/dl,
as recommended by EMEA. There are no published data regarding
predictive factors of response to epoetin during antiviral therapy.
In other diseases, an increase in hemoglobin of at least 1 g/dl in
the 4th week of EPO as well as low baseline levels of endogenous
erythropoietin (in most studies the cut-off value is 100 mU/ml)
are two parameters that have been signiﬁcantly associated with
response to EPO. Conversely, elevated baseline levels of erythro-
poietin (>500 mU/ml) and deﬁcits of iron, vitamin B12 or folate
have been associated with absence of response [24–26].
A lack of response to epoetin can be due to 3main factors: (a)
lack of time, i.e., the decrease in the levels of hemoglobin is very
rapid and theEPOcannotpromote amarrowresponsewithenough
celerity. It is estimated that erythropoietin requires about 3 weeks
to generate an increase in the productionof erythrocytes. Hence, in
order to deal appropriately with this complication, anticipation is1328 Journal of Hepatology 2013crucial so that EPO therapy can be initiated before the ﬁrst signs
of progressive anemia develop; (b) the type of anemia, i.e., in
patients with central type anemiawith bonemarrow suppression;
(c) functional iron deﬁcit. Indeed, absolute and functional iron def-
icit is the principal reason for the lack of response to epoetin in cir-
cumstances other than hematological neoplasm. If EPO is
considered, levels of ferritin should not be <100 mg/dl and trans-
ferrin saturation not be <20%. In these cases, the administration
of parenteral iron can increase the possibilities of response to
EPO treatment. On rare occasions, there is B12 and, particularly,
folate deﬁciency due to excessive consumption as a result of the
expansion of the red cell population. Since these deﬁcits occur
infrequently, the systematic use of B12 and folate is not recom-
mended, and should only be prescribed if a deﬁcit has been
detected by laboratory analysis; (d) erythropoietin resistance,
which is observed in patients with plasma levels of erythropoietin
>500 IU/L. Normal levels of endogenous erythropoietin vary
between 10 IU/L and 30 IU/L. In patients with chronic hepatitis C
treated with antivirals, a linear increment in the levels of endoge-
nous erythropoietin occurs as anemia develops, with levels stabi-
lizing around 200–400 IU/L. In patients with very high levels of
erythropoietin, the use of exogenous EPO is not indicated due to
the low probability of inducing a response.
Packed red cell transfusions are indicated when hemoglobin
decreases to less than 7.5 g/dl and/or there are clinical symptoms
and/or there is no response to other therapeutic measures. The
transfusion of 400 ml packed cells should result in an increase
in hemoglobin levels of 1.5 g/dl. Hence, the recommendation is
to transfuse 2–3 units of packed cells to solve an acute episode
while, at the same time, avoiding complications resulting from
overload if larger quantities are administered.
In conclusion, the clinical status should guide our strategy to
manage anemia. Usually, a decrease in the concentration of
hemoglobin to less than 10 g/dl is associated with clinical symp-
toms requiring ribavirin dose reduction. If the levels of hemoglo-
bin continue to decrease and/or symptoms do not improve,
epoetin should be administered. In severe cases of anemia
(hemoglobin 67.5 g/dl, hemodynamic instability), a transfusion
may be required. This is especially relevant for patients with
comorbidities, older age or ischemic heart disease. In these
patients, the dose of PegIFN should be reduced at the same timevol. 59 j 1323–1330
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as ribavirin, when hemoglobin decreases to <10 g/dl. Triple ther-
apy should be discontinued when there is a decrease in the
hemoglobin level below 7 g/dl and/or when there is hemody-
namic compromise (decrease of 2 g/dl in 2 weeks, 3 g/dl in
4 weeks, or 4 g/dl from baseline hemoglobin) and stabilization
of hemoglobin >8.5 g/dl has not been achieved following the
use of transfusion of packed red cells. If ribavirin is discontinued
for a prolonged period of time due to lack of response, protease
inhibitors should be discontinued as well.Do the incidence, natural course and management of anemia
differ in the liver transplantation setting?
In liver transplant recipients treated with PegIFN/RBV, treatment
is associated with several adverse effects, particularly hemato-
logic toxicity; the management has been treatment discontinua-
tion and dose reductions in approximately 27% and 73% of
patients, respectively [27–29]. Dose reduction or discontinuation
of therapy due to anemia has been reported in 22% to 40% of trea-
ted recipients [30]. While the mechanisms involved in the devel-
opment of anemia, such as interferon-related bone marrow
suppression, myelosuppression due to concomitant therapies,
renal insufﬁciency, HCV-interference with erythropoietic produc-
tion, and, above all, ribavirin dose-dependent hemolysis are the
same as those described in the immune competent population,
their prevalence, particularly that of renal insufﬁciency and
myelosuppression due to concomitant therapies, is higher in
the liver transplant setting. In a recent study based on 164 liver
transplant patients (75% men; mean age 55 years, range: 35–
75) treated with PegIFN/RBV, 70% of patients developed anemia
(hemoglobin <10 g/dl) and 40% developed signiﬁcant anemia
(hemoglobin drop >5 g/dl). Factors independently associated
with anemia, and more speciﬁcally with the signiﬁcant anemia,
included renal insufﬁciency (RR: 0.97, 95%CI: 0.95–0.99;
p = 0.03), longer time from transplantation to therapy (RR:
1.001, 95%CI:1.000–1.001; p = 0.002), high baseline viremia (RR:
3.2, 95%CI: 1.3–8.1, p = 0.01), cyclosporine-based immunosup-
pression (RR: 0.4, 95%CI: 0.2–0.99; p = 0.049), and use of mico-
phenolate mofetil (RR: 3.4, 95%CI: 1.1–10.7; p = 0.03). Anemia
was not associated with early viral response, end-of-treatment
response, relapse or sustained viral response, PegIFN dose reduc-
tion or premature treatment discontinuation, but resulted in
ribavirin dose reductions (p = 0.0001) [31]. Data with triple ther-
apy in the liver transplant setting are still preliminary but, as
with cirrhotic patients, it seems that adverse events, particularly
anemia, are more frequent and severe compared to those seen
with dual therapy. In a recent report on 18 boceprevir- and 19
telaprevir-treated liver transplant recipients, 100% and 84%
developed anemia, which was severe (<8 g/dl) in 39% and 15%,
respectively. Epoetin was used in >90% of cases, transfusions in
33% and 16%, respectively, and ribavirin dose reductions were
required in more than two third of cases [32]. As with dual ther-
apy, anemia did not seem to have an effect on on-treatment viral
response. No data on sustained viral response have been pro-
vided, as yet. In conclusion, in liver transplant patients with
recurrent hepatitis C treated with PegIFN/RBV, anemia is a very
frequent complication, with almost 70% of patients developing
a hemoglobin of <10 g/dl compared to 30% in immune competent
patients, and a reduction of hemoglobin >5 g/dl in 41% of treated
patients compared to 20–25% in non-transplanted patients.Journal of Hepatology 2013Anemia results in ribavirin dose reductions and frequent use of
EPO (60% compared to only 15% in immune competent patients
treated with dual therapy). Adding a protease inhibitor to Peg-
IFN/RBV results in increased incidence and severity of anemia
and, as a consequence, a greater need for epoetin, transfusions
and ribavirin dose reductions [32].
Key Points 1
In the registration trials, triple therapy with boceprevir or 
telaprevir was associated with an increase in the incidence 
and severity of anemia in comparisons with PegIFN plus 
ribavirin
Key Points 2
The incidence of anemia is even greater in real practice 
cohorts, especially in advanced fibrosis and in transplanted 
patients
Key Points 3
Age, female gender, low baseline hemoglobin and cirrhosis 
are the main factors associated with higher incidence of 
anemia during triple therapy
Key Points 4
Ribavirin dose reduction should be the preferred first 
strategy for anemia management. Epoetin belongs to the 
second line and pack red blood transfusion are eventually 
needed in a subgroup of patients
Key Points 5
The reduction of ribavirin does not adversely impact the 
ultimate SVR rate. This information is not very robust in 
difficult-to-cure patients, especially in patients with cirrhosis
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